CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 31 enrolled
Drug / intervention
VTAMA (tapinarof) cream, 1%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05789576
NCT05789576Phase 4Completed
CompareCT.gov

A Phase 4, Open-label Study to Investigate the Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in the Treatment of Plaque Psoriasis Occurring in the Head and Neck Region

Organon and Co·interventional·Posted Mar 29, 2023·Updated Jun 12, 2025

In Brief

A Phase 4 clinical trial evaluating VTAMA (tapinarof) cream, 1% for Psoriasis. Completed, enrolled 31 participants across 10 sites.

Detailed Summary

This is an open-label, multi-center study to evaluate the efficacy and safety of VTAMA (tapinarof) cream, 1% in adults with plaque psoriasis occurring in the head and neck region

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedMar 29, 2023
Enrollment StartMar 13, 2023
Primary CompletionJun 30, 2023
Study CompletionJul 19, 2023
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 3.3 years ago

Interventions

VTAMA (tapinarof) cream, 1%drug

VTAMA (tapinarof) cream, 1% applied topically once daily